Global analysis shows widespread eligibility for GLP-1 weight management drugs

The worldwide prevalence of obesity has more than doubled in the last three decades, bringing with it an increase in weight-related diseases like diabetes, cardiovascular disease, and cancers. This public health crisis strains global healthcare systems and economies, but a new study co-led by investigators from Mass General Brigham could inform strategic programs to make GLP-1 medications part of the solution.

Mass General Brigham researchers and collaborators from Washington University School of Medicine in St. Louis and Emory University's Rollins School of Public Health pooled data from 99 countries and 810,635 adults to determine how many people worldwide may benefit from GLP-1 use. They found more than one-in-four adults would be eligible for GLP-1s for weight management, with women, older individuals, and low- and middle-income countries among the most eligible. These critical metrics could be formative in policy development to deploy GLP-1s around the world to tackle obesity and its comorbidities. Their results are published in a research letter in The Lancet Diabetes & Endocrinology.

There has never been such a potentially transformational and scalable tool for obesity, type 2 diabetes, and other health-related complications of obesity. For so many decades, we told everyone the problem was you-you need to move more and eat less, then you won't struggle with this problem. GLP-1 receptor agonists have allowed us to really understand that biology is much more powerful than that, and 'eat less, move more' is just an oversimplified way to think about things."

Jennifer Manne-Goehler, MD, ScD, co-senior author, physician in the Division of Infectious Diseases at Brigham and Women's Hospital and Department of Medicine at Mass General Brigham

The power and promise of GLP-1s has been recognized by the World Health Organization (WHO), as they actively are working to make them standard, accessible mediations. But scaling up production and rolling out application of GLP-1s globally starts with one big question: Exactly how many people need them?

"Given the steadily increasing prevalence of obesity, it's not surprising that our analysis found that more than one quarter of adults around the world may be eligible for this medication," said corresponding author Sang Gune K. Yoo, MD, who conducted this work as a research fellow in cardiology at WashU Medicine. "This medication has the potential to help many individuals, although further research is needed to better understand its long-term safety and sustainability. Access remains a major challenge as these medications are difficult to obtain in many settings. Most importantly, we must continue to invest in and develop effective non-pharmacological strategies for the prevention and treatment of obesity, an area where substantial gaps remain."

corresponding author Sang Gune K. Yoo, MD, who conducted this work as a research fellow in cardiology at WashU Medicine

The researchers started with household health survey data collected from 99 countries between 2008 and 2021. A total of 810,635 adults between 25 and 64 years old were pooled based on availability of diabetes biomarkers, blood pressure and BMI measurements, and hypertension and diabetes diagnostic history. Those that had a BMI of more than 30 or a BMI of more than 27 with additional hypertension, diabetes, or both, were deemed eligible for GLP-1 use.

Globally, 27% of the adults were eligible for GLP-1s for weight management-four-fifths of whom came from low- and middle-income countries. Eligibility rates were highest in Europe and North America (42.8%) and the Pacific Islands (41.0%). Women were also more likely (28.5%) than men to be eligible, as were older individuals more likely (38.3%) than their younger counterparts (17.9%).

"These socioeconomic and gender eligibility percentiles are especially staggering," added Manne-Goehler. "As of last year, type 2 diabetes was the top cause of death for women in South Africa. There are parts of the world where women can really benefit from these medicines, and it's our job to see through their implementation."

"Global access to GLP-1s is a question of health equity," said co-lead author Felix Teufel, MD, from Emory University's Rollins School of Public Health. "The goal is to ensure large-scale access for people who would benefit most – not just those easiest to reach."